Press release
Lawsuit filed for Investors who lost money with shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
A lawsuit was filed on behalf of investors in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and for certain investors are short and strict deadlines running. Deadline: July 14, 2025. NASDAQ: IOVA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
San Carlos, CA based Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company's key product is Amtagvi, an autologous T cell immunotherapy to treat adults with unresectable or metastatic melanoma.
On July 25, 2024, Iovance Biotherapeutics, Inc. announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on 1) "the iCTC completed annual scheduled maintenance in December" and "capacity was reduced by more than half for about 1 month," 2) "[l]ower Proleukin sales" than the company expected, and 3) "the variable pace at which ATCs began treatment patients."
On May 8, 2025, Iovance Biotherapeutics, Inc released their Q1FY25 results below expectations and significantly lowered fiscal year 2025 projections.
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) declined from $12.51 per share on November 07, 2024, to as low as $1.65 per share on May 09, 2025.
The plaintiff claims that between August 8, 2024, to May 8, 2025, the defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers.
Those who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) here
News-ID: 4041114 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of Zynex, Inc. (NASDAQ …
An investigation was announced for long-term investors in shares of Zynex, Inc. (NASDAQ: ZYXI) concerning potential breaches of fiduciary duties by certain directors of Zynex, Inc.
Investors who are current long term investors in Zynex, Inc. (NASDAQ: ZYXI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in Zynex, Inc. (NASDAQ:…
Investors who lost money with shares of Elevance Health, Inc. (NYSE: ELV) should …
An investor in shares of Elevance Health, Inc. (NYSE: ELV) filed a lawsuit over alleged violations of Federal Securities Laws by Elevance Health, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Elevance Health, Inc. (NYSE: ELV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 11, 2025. NYSE: ELV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Lawsuit filed for Investors who lost money with Bitfarms Ltd. (NASDAQ: BITF) sha …
An investor, who purchased shares of Bitfarms Ltd. (NASDAQ: BITF), filed a lawsuit over alleged violations of Federal Securities Laws by Bitfarms Ltd. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Bitfarms Ltd. (NASDAQ: BITF) have certain options and for certain investors are short and strict deadlines running. Deadline: July 8, 2025. NASDAQ: BITF investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit filed for Investors who lost money with shares of Compass Diversified (N …
An investor, who purchased shares of Compass Diversified (NYSE: CODI), filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by Compass Diversified.
Investors who purchased shares of Compass Diversified (NYSE: CODI) have certain options and for certain investors are short and strict deadlines running. Deadline: July 8, 2025. NYSE: CODI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
More Releases for Iovance
Malignant Melanoma Pipeline Assessment | Insights into the Current Therapies, Em …
"Malignant Melanoma Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Malignant Melanoma Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products…
Small Lymphocytic Lymphoma Pipeline Assessment | Insights into the Current Thera …
As per DelveInsight's assessment, globally, nearly 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Small Lymphocytic Lymphoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.
"Small Lymphocytic Lymphoma Pipeline Insight, 2022" report by DelveInsight provides a comprehensive…
Tumor-Infiltrating Lymphocytes Market to Bolster the Growth during the Forecast …
Tumor-Infiltrating Lymphocytes Therapy exhibits significant potential for the treatment of advanced melanoma in clinical environments. ATMPs, in general, are reckoned as a personalized approach for cancer treatment. Tumor-infiltrating lymphocytes (TILs) are an important prognostic factor in melanoma and are associated with better outcomes in epithelial ovarian cancer.
An increase in focus on developing tumor-infiltrating lymphocytes due to several benefits contributes to the growth of the global tumor-infiltrating lymphocytes market. The National…
Tumor Infiltrating Lymphocyte (TIL) Market Key Players and Production Informatio …
The new study on the Global Tumor Infiltrating Lymphocyte (TIL) Market 2021-2027 analyzes the crucial capabilities, key infrastructures, major organizations, evaluates measures to attain potential success in the Tumor Infiltrating Lymphocyte (TIL) industry. Because of the in-depth overview of the world Tumor Infiltrating Lymphocyte (TIL) market, the recent document allows investors, traders, and manufacturers to plan some innovative techniques, and meanwhile, align them with operational and commercial enterprise models. Additionally, the Tumor…
Tumor Infiltrating lymphocytes Market to Bolster the Growth during the Forecast …
Tumor Infiltrating Lymphocytes Therapy, exhibit significant potential for the treatment of advanced melanoma in clinical environments. ATMPs, in general, are reckoned as personalized approach for cancer treatment.
Tumor infiltrating lymphocytes (TILs) are an important prognostic factor in melanoma and are associated with better outcomes in epithelial ovarian cancer.
Increase in focus on developing tumor infiltrating lymphocytes due to several benefits contributes to the growth of global tumor infiltrating lymphocytes market.
The…
Investigation announced for Long-Term Investors in shares of Iovance Biotherapeu …
Certain directors of Iovance Biotherapeutics, Inc are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Iovance Biotherapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Carlos, CA based Iovance Biotherapeutics,…
